Glanbia H1 2026 slides: 30% EPS growth, upgraded guidance

Glanbia (GLAPY) raised its FY2026 outlook after delivering strong 1H2026 results: adjusted EPS of 81.24 cents (+30.0% constant currency) on revenue of $2.1B (+7.0%) and EBITDA up 14.1% to $275.4M. Performance Nutrition was the key driver with like-for-like revenue +16.9% (Optimum Nutrition +25.2% like-for-like) and improved group EBITDA margin (+80bps to 13.2%) despite rising input costs. Management lifted guidance to +17% to +20% constant-currency adjusted EPS growth and boosted capital returns with a +10% interim dividend and a completed €100M share buyback, while flagging margin risks from higher whey costs in 2027 and ongoing raw-material inflation.

Analysis

The market is likely still underestimating how much of the upside is coming from mix and distribution rather than one-off price discipline. That matters because branded nutrition with repeat purchase and channel breadth can reprice faster than commodity food businesses, so the earnings power is more durable than a simple inflation pass-through story. The flip side is valuation: after a big year-to-date rerate, this is now a quality compounder that needs clean quarters, not a cheap cyclical recovery.

The second-order winner is not just the company itself but the broader protein and sports-nutrition ecosystem: weaker private-label and smaller supplement brands will struggle to match shelf-space velocity if pricing stays firm and innovation keeps driving velocity. Upstream whey and protein ingredient suppliers also gain pricing power, but the margin pressure in the health ingredients arm shows that input inflation can still leak through with a lag, especially in petrochemical-linked raw materials. That creates a split tape inside packaged nutrition: branded names outperform while contract-manufacturing and lower-moat players absorb the squeeze.

The main risk window is 1-3 quarters, not today: if management needs another price round into late 2026/early 2027 and unit growth decelerates, the narrative shifts from durable growth to elastic demand. Falsifiers would be a meaningful slowdown in U.S. measured-channel sell-through, a stall in margin expansion, or evidence that higher whey costs are not fully offset by the transformation program. Over 6-18 months, the stock probably lives or dies on whether operating leverage can keep outrunning inflation after the easy recovery has already been priced in.

Key Decisions for Investors

• Long GLAPY on pullbacks over the next 2-4 weeks; use it as a quality-growth compounder, but do not chase after a 56% YTD move. Risk/reward is best if the stock digests gains while the sell-side raises FY26-27 estimates.
• Pair long GLAPY vs short XLP for a 1-3 month relative-value trade to isolate branded nutrition pricing power from broader staples beta. Thesis breaks if GLAPY loses margin momentum or if XLP catches a defensive rotation bid.
• Set an alert for the next quarterly update and 2027 pricing commentary; if U.S. sell-through slips or another price increase triggers volume deceleration, trim 30-50% of the long. This is the key catalyst that can reverse the move.
• No standalone short yet; wait for evidence that whey inflation is not being offset before fading the name. A short only works if the company is forced into price-led growth with flat to negative unit elasticity.